Why health tech start-ups run out of runway
Most health technology companies do not fail because the technology was wrong. They fail because the time between building something valuable and being paid for it at scale is longer than the money they raised to cross it.
That gap has a structure, and it is worth understanding before you plan a funding round.
The timelines are longer at every stage
Development takes longer, because safety, quality and integration work run alongside features. Approval takes longer, particularly where a notified or approved body is involved; reported review timelines for higher-risk devices in the EU run to roughly 12 to 24 months (ElendiLabs, 2026). Selling takes longer, with industry analyses reporting buying cycles beyond a year for most healthcare organisations and several stakeholders required to approve a purchase (MagmaLabs, 2025). Adoption takes longest of all: one frequently cited estimate put routine NHS adoption of new diagnostic technologies at around a decade (Forbes, 2025).
These delays compound rather than overlap. A company that budgets consumer-software timelines into a health technology plan is not optimistic; it is mis-specified.
Evidence costs money you have to spend before revenue
Buyers want evidence, and the evidence they want is rarely the evidence you already have. NICE’s evidence standards framework sets expectations for digital health technologies and refers to the wider NHS assurance requirements including DTAC, DCB0129 and DCB0160 (NICE). NICE’s early value assessment route, launched in 2022, exists partly to let promising technologies be used while evidence is generated (HTA commentary, 2025).
Evidence generation has its own timeline: design, approvals, recruitment, follow-up, analysis, publication. Each stage sits before the revenue it unlocks. Research with SMEs has identified high market entry costs, complex regulatory and procurement frameworks and limited access to decision makers as central barriers (PLOS One, 2025).
Pilots consume cash and imitate progress
The pilot is where many health technology companies spend their most productive year. Pilots require configuration, integration, training, support and reporting, usually at little or no cost to the customer, and frequently end without a purchasing decision because no budget was identified at the outset.
Policy is moving to reduce the duplication. The 10 Year Health Plan promises an innovator passport, so that technology assessed robustly by one NHS organisation can be taken up by others without repeat assessment, delivered through the MedTech Compass platform (National Health Executive). Until that is operating at scale, treat every pilot as a cost centre with an exit condition attached.
Budgets do not behave like subscriptions
Public healthcare budgets are annual, split between capital and revenue, and heavily focused on in-year cost. Industry consultation has highlighted that this makes it difficult to fund technologies whose benefits accrue over several years, even where the case is strong (Global Counsel and ABHI). Programmes such as the MedTech Funding Mandate exist to help overcome financial barriers to adoption for eligible technologies, but eligibility is specific and not a general route.
For a small company, the practical effect is that revenue arrives in lumps tied to financial years, not in a smooth curve, and cash flow planning has to reflect that.
Talent and attention are finite
Small health technology teams need clinical, regulatory, quality, security, data protection and commercial expertise. Few can employ all of it. The result is that a founder ends up personally responsible for regulatory strategy, information governance and NHS business development at the same time as running the company, and each area gets a fraction of the attention it needs. This is a leading cause of avoidable delay, and it is often invisible until a deadline exposes it.
What actually helps
- Model the real timeline. Build the funding plan around evidence, assurance and procurement timelines, not around product milestones.
- Choose a beachhead. One pathway, one buyer type, one geography. Repeatability beats breadth when cash is finite.
- Make pilots conditional. Agree measures, decision makers and the budget route before you start.
- Sequence evidence against claims. Generate the evidence your claim requires, in the order buyers will ask for it.
- Look for non-dilutive support. Innovation funding, health innovation networks, accelerator programmes and sector grant schemes can fund exactly the work that delays revenue.
- Buy expertise in slices. Fractional or project-based specialists cost less than the delay caused by learning each discipline from scratch.
None of this makes healthcare a fast market. It does make the crossing survivable, which is the actual objective.
How FastForward can help
We work with health technology founders and leadership teams on the commercial realities between a working product and sustainable revenue.
- Commercial and funding runway planning. Realistic timelines for regulatory, assurance, evidence and procurement milestones, and what they mean for your raise.
- Beachhead strategy. Choosing the first market where you can win repeatedly rather than occasionally.
- Evidence planning. The minimum credible evidence package for the claims you need to make, sequenced against sales.
- Fractional senior capacity. Regulatory, market access and commercial leadership without permanent hires.
To talk about your plan, email hello@fwdtech.co.uk.
References
1. ElendiLabs (2026), EU medical device regulation in 2026 — https://elendilabs.com/en/articles/eu-medical-device-regulation-2026-comprehensive-analysis
2. MagmaLabs (2025), Why most HealthTech startups fail — https://blog.magmalabs.io/2025/04/01/why-most-healthtech-startups-fail-in-2025.html
3. Forbes (2025), Improving the pathway from SME innovation to NHS adoption — https://www.forbes.com/sites/drkathmackay/2025/08/29/improving-the-pathway-from-sme-innovation-to-nhs-adoption/
4. NICE, Evidence standards framework for digital health technologies — https://www.nice.org.uk/corporate/ecd7/resources/evidence-standards-framework-for-digital-health-technologies-pdf-1124017457605
5. Health Technology Assessment commentary (2025), NICE’s early value assessment — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12555772/
6. PLOS One (2025), Overcoming barriers to NHS adoption of innovative IPC products — https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0331688
7. National Health Executive, New innovator passport — https://www.nationalhealthexecutive.com/articles/revolution-nhs-new-innovator-passport-slashes-red-tape-and-speeds-life-saving-tech
8. Global Counsel and ABHI, Unleashing innovation in the NHS — https://www.global-counsel.com/insights/report/unleashing-innovation-nhs-barriers-and-opportunities-adoption-and-uptake-healthcare